NEW YORK (TheStreet) -- RATINGS CHANGES
CME (CME) was initiated with a buy rating at Deutsche Bank. Twelve-month price target is $85. Company is leveraged to higher trading volume, especially in futures, Deutsche Bank said.
Express Scripts (ESRX) was downgraded at Goldman Sachs to neutral from buy. Twelve-month price target is $75. Core business is facing fading growth drivers, Goldman said.
Frank's International (FI) was initiated with a sell rating at TheStreet Ratings.
Read More: Warren Buffett's Top 10 Dividend Stocks
JDS Uniphase (JDSU) was upgraded at RBC Capital to outperform from sector perform. Twelve-month price target of $18 based on a sum-of-the-parts valuation, RBC Capital said.
Jones Lang Lasalle (JLL) was upgraded at J.P. Morgan to overweight from neutral. Estimates were also increased, given strong asset pricing and rental demand, J.P. Morgan said.
Macy's (M) was downgraded at Sterne Agee to neutral from buy. Twelve-month price target is $62. Valuation call, as yellow flags have recently emerged, Sterne Agee said.
Medtronic (MDT) was initiated with a neutral rating at Sterne Agee. Twelve-month price target is $68. Company lacks near-term catalysts, Sterne Agee said.
Nasdaq OMX (NDAQ) was initiated with a hold rating at Deutsche Bank. Valuation call, based on a 12-month price target of $46, Deutsche Bank said.
Nortel Inversora (NTL) was downgraded to hold at TheStreet Ratings.
Omnicare (OCR) was upgraded at Goldman Sachs to buy. Twelve-month price target is $76. Generic business can drive growth and the company has untapped strategic value, Goldman said.